Korsana (KRSA) Director Nimish Shah Receives Option Award

What Happened
Nimish Shah, a director of Korsana Biosciences, was granted an option representing the right to purchase 48,445 shares of the company's common stock on 2026-09-09. The grant is reported as a derivative award (transaction code A) with reported acquisition amount $0.00 — it is an option grant, not an immediate purchase or sale. The option vests in equal monthly installments through September 9, 2029, subject to Shah's continued service.

Key Details

• Transaction date: 2026-09-09; Form 4 filed: 2026-09-10 (timely filing).
• Transaction type/code: A (award/grant of an option). Reported acquisition price: $0.00.
• Option size: right to purchase 48,445 shares. Vesting: equal monthly installments through 9/9/2029 (see footnote).
• Shares owned after transaction: not specified in the filing.
• Footnotes:
  • F1: Vesting schedule detail (monthly through 9/9/2029, subject to continued service).
  • F2: Under an agreement with Venrock Management, LLC, Shah is deemed to hold the option for the sole benefit of the Management Company and must exercise only at its direction; Shah disclaims beneficial ownership except for any pecuniary interest.

Context
This filing documents a grant of options (a derivative award) — not an exercise or sale — so there was no immediate purchase, sale, or change in outstanding common shares until/unless the option is exercised. Director option grants are common as compensation/retention tools; the Venrock Management LLC note indicates the economic interest may be held or directed by an affiliated management company rather than Shah directly.